for eMaxHealthCarrington Laboratories, Inc.'s DelSite Biotechnologies subsidiary, an innovator in nasal vaccine delivery technology, said flu vaccines delivered nasally have been shown to provide immunity both locally in the nasal passages and also systemically as the vaccine penetrates the nasal mucosa.
"This feature of double immunity, and the speed with which the nasal passages become protected, can be very beneficial in immunizing children with immature immune systems and older people with weakened immune systems," notes Dr. Yawei Ni, senior scientist at DelSite Biotechnologies.
"The results reported today in The New England Journal Of Medicine on the enhanced efficacy of FluMist
eMaxHealth welcomes yourcomments and feedback on this story without registration, but keep the comments meaningful please. Links are not accepted.
